| Name | Title | Contact Details |
|---|
MAS is at the forefront of Singapores rapidly growing financial industry, creating new policies and initiatives that address the ever-changing landscape. Work at MAS promises not only challenges worthy of your intellectual abilities, but also the personal satisfaction that comes from building one of Asias premier financial hubs. We invite you to take up the challenge and make a difference to Singapores economic and financial development! At MAS, we place a great emphasis on developing a vibrant and conducive work environment that motivates each and every employee to make a meaningful contribution to the organisation. Our people recognize the importance of upholding our values to achieve more together. We believe that it is essential that our people enjoy working here with one another. MAS Functions - To act as the central bank of Singapore, including the conduct of monetary policy, the issuance of currency, the oversight of payment systems and serving as banker to and financial agent of the Government - To conduct integrated supervision of financial services and financial stability surveillance - To manage the official foreign reserves of Singapore - To develop Singapore as an international financial centre
Progress is achieved by those with the courage to reimagine whats possible. Audi was born more than a century ago with a vision of boldly challenging the status quo and is bound by a promise to imaginatively innovate. We believe the best ideas—the ideas that will define our future—will come from new ways of thinking. We believe everyone should have a voice. We believe in equality. We believe that "we" includes all of us. For these reasons, we strive to create a workplace where diverse ideas are embraced, where people can be themselves, and where everyone comes together to reinvent mobility, drive toward a more sustainable future and create amazing customer experiences.
Syensqo is a leading science company whose ground-breaking technologies revolutionize the way we live. Our purpose is to advance human progress while cultivating a future for our planet that is not only safer and cleaner, but also inherently more sustainable, driven by the principles of circular economy. Our disruptive, market-leading solutions address fundamental megatrends. We play a key role in the future of clean mobility and bring about breakthroughs in biotechnology, natural ingredients, and circular solutions, contributing to sustainable, high-performance products for homes, food and consumer goods, planes, cars, smart devices, and healthcare applications. Inspired by the scientific councils, which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates in 30 countries.
Atlas Copco Group enables technology that transforms the future. We innovate to develop products, services and solutions that are key to our customers success. Our four business areas offer compressed air and vacuum solutions, energy solutions, dewatering and industrial pumps, industrial power tools and assembly and machine vision solutions. In 2023, the Group had revenues of BSEK 173, and at year end about 53 000 employees.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.